(Q33402188)

English

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

peritoneal carcinoma

1 reference

based on heuristic

inferred from title

Isabelle Ray-Coquard

6

object named as

Isabelle Ray-Coquard

0 references

Ursula A. Matulonis

1

object named as

Ursula A Matulonis

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Sudarshan Sharma

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sharad Ghamande

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael S Gordon

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Salvatore A Del Prete

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Elzbieta Kutarska

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hua Liu

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Howard Fingert

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xiaofei Zhou

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hadi Danaee

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Russell J Schilder

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

5 July 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

127

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

63-69

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Management of relapsed/refractory epithelial ovarian cancer: current standards and novel approaches

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Novel strategies for reversing platinum resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Aurora kinase inhibitors--rising stars in cancer therapeutics?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Functional significance of Aurora kinase A regulatory interactions with p53-ERα complex in human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Predictive value of Aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Clinical trials in ovarian carcinoma: study methodology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.06.040

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.06.040

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33402188&oldid=2046310887"